共 249 条
[1]
Engstrom PF(2009)NCCN clinical practice guidelines in oncology: colon cancer J Natl Compr Cancer Netw 7 778-831
[2]
Arnoletti JP(2013)Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 1023-1034
[3]
Benson AB(2015)FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer Eur J Cancer 51 12431252-700
[4]
Chen YJ(2015)Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer J Clin Oncol 33 692-177
[5]
Choti MA(2011)An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer Clin Colorectal Cancer 10 171-339
[6]
Cooper HS(2011)The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status Clin Colorectal Cancer 10 333-2247
[7]
Covey A(2014)PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer J Clin Oncol 32 2240-1502
[8]
Dilawari RA(2011)Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment Br J Cancer 105 1495-iv187
[9]
Early DS(2014)Tumour shrinkage and response outcomes during second-line panitumumab (pmab) + FOLFIRI vs FOLFIRI treatment Ann Oncol 25 iv186-72
[10]
Enzinger PC(2012)First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer J Cancer Res Clin Oncol 138 65-190